The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits.
In 3-month-old homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits the effect of treatment with the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor pravastatin was studied for 9 months and related to the endothelial function of the coronary arteries of isolated hearts and rings of the distal abdominal aorta. Oral administration of pravastatin in doses up to 40 mg/kg per day significantly decreased plasma cholesterol by 51% in comparison to untreated WHHL rabbits. Basal coronary flow and bradykinin-induced increase in coronary flow in Langendorff hearts of the pravastatin-treated animals were significantly greater than the flow in the control animals, whereas the metacholine-induced relaxation of abdominal aortic rings was not different and attenuated in comparison to New Zealand white rabbits. The incidence of atherosclerotic lesions in four main coronary arteries and the aorta was significantly lower in the pravastatin treated animals (25.0% and 52.8% respectively) than in untreated WHHL rabbits (34.1% and 80.0% respectively). The mean percentage of narrowing in the aorta was also significantly lower in the pravastatin-treated group (12.0%) than in the controls (25.2%). Significant correlations were found between the extent of atherosclerotic lesions and the bradykinin-induced increase in coronary flow versus plasma total cholesterol levels. Thus, in this model, long term cholesterol lowering treatment with pravastatin starting at an early age retards the progression of plaque formation and preserves the endothelium-dependent relaxation of the coronary arteries.
Kroon
A A
AA
Department of General Internal Medicine, University Hospital Nijmegen, Netherlands.
Stalenhoef
A F
AF
Buikema
H
H
Demacker
P N
PN
de Wilde
P C
PC
Leijten
P A
PA
van Gilst
W H
WH
D000818:Animals; D001011:Aorta / Q000473:pathology / Q000503:physiopathology; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D001920:Bradykinin / Q000494:pharmacology; D002784:Cholesterol / Q000097:blood*; D003326:Coronary Circulation / Q000187:drug effects; D004730:Endothelium, Vascular / Q000473:pathology / Q000503:physiopathology*; D005260:Female; D066298:In Vitro Techniques; D008055:Lipids / Q000097:blood; D008297:Male; D016210:Methacholine Chloride / Q000494:pharmacology; D017035:Pravastatin / Q000627:therapeutic use; D011817:Rabbits; D012977:Sodium Nitrite / Q000494:pharmacology; D014664:Vasodilation
D008055:Lipids; D016210:Methacholine Chloride; D002784:Cholesterol; D017035:Pravastatin; D012977:Sodium Nitrite; D001920:Bradykinin